Additional file 1 of Injectable hydrogel-based combination therapy for myocardial infarction: a systematic review and Meta-analysis of preclinical trials
Creators: name: Gao, Han
name: Liu, Song
name: Qin, Shanshan
name: Yang, Jiali
name: Yue, Tian
name: Ye, Bengui
name: Tang, Yue
name: Feng, Jie
name: Hou, Jun
name: Danzeng, Dunzhu
Publisher: name: figshare
Year: 2024
Subjects: subject: Space Science
subject: Medicine
subject: Immunology
subject: FOS: Clinical medicine
subject: Biological Sciences not elsewhere classified
subject: Science Policy

description: Additional file 1: Supplement Table 1. PRISMA Checklist. PRISMA Checklist From: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(6): e1000097. doi:10.1371/journal.pmed1000097. Supplement Table 2. Detailed search strategy. Supplement Table 3. Study inclusion and exclusion criteria. Supplement Table 4. Study quality assessment using the Heyland methodological quality. score. Supplement Table 5. A. Ejection Fraction. B. Fractional Shortening. C. End Systolic Diameter. D. End Diastolic Diameter. E. End Diastolic Volume. F. End Systolic Volume. G. Infact size. H. Wall thickness. Continuous a priori subgroup analyses on (A) Ejection Fraction and (B) Fractional Shortening, (C) End Systolic Diameter, (D) End Diastolic Diameter, (E) End Systolic Volume, (F) End Diastolic Volume, (G) Infarct Size, and (H) Wall Thickness in the included studies. β is the slope derived from meta-regression analyses and represents the treatment effect of stem cell embedded scaffolds compared to independent injections of cells for primary and secondary outcomes in the included studies. The residual I2 value indicates heterogeneity unexplained by the subgroup and is reported as a percent value, where I2 ≤ 50% indicated “moderate” heterogeneity, I²≥ 50% indicated “substantial” heterogeneity, and ≥ 75% indicated “considerable” heterogeneity. P-value significance for heterogeneity was set as P &lt; 0.10. Supplement Figure 1. Cochrane risk of bias tool to asses Selection Bias, Performance Bias, Detection Bias, Attrition Bias, and Reporting Bias in studies investigating the effects of stem cell-embedded scaffolds on cardiac repair. Authors’ judgments concerning each risk of bias item are presented as percentages across all included studies. Supplement Figure 2. A. End Systolic Diameter. B. End Diastolic Diameter. C. End Systolic Volume. D. End Diastolic Volume. E. Infarct Size. F. Wall Thickness. Forest plots of all trials investigating the effect of hydrogel combination therapy on left ventricular (A) End Systolic Diameter, (B) End Diastolic Diameter, (C) End Systolic Volume, (D) End Diastolic Volume, (E) Infarct Size, and (F) Wall Thickness in the included studies. Pooled effect estimates (diamonds) are shown: one each for trials using hydrogels, patches, microspheres/beads, and their combination (total). Data are expressed as weighted mean differences with 95% CIs, using generic inverse-variance random-effects models. Between-studies heterogeneity was tested by using the Cochran Q statistic (chi-square) at a significance level of P &lt; 0.05. Reference numbers for each study can be found in Table 1 and list of references. Supplement Figure 3. A. EF. B. FS. C. End Systolic Diameter. D. End Diastolic Diameter. E. End Systolic Volume. F. Infarct Size. G. Wall Thickness. Forest plots of all trials investigating the effect of hydrogel combination multitherapy on left ventricular (A) EF, (B) FS, (C) End Systolic Diameter, (D) End Diastolic Diameter, (E) End Systolic Volume, (F) Infarct Size, and (G) Wall Thickness in the included studies. Pooled effect estimates (diamonds) are shown: one each for trials using hydrogels, patches, microspheres/beads, and their combination (total). Data are expressed as weighted mean differences with 95% CIs, using generic inverse-variance random-effects models. Between-studies heterogeneity was tested by using the Cochran Q statistic (chi-square) at a significance level of P &lt; 0.05. Reference numbers for each study can be found in Table 1 and list of references. Supplement Figure 4. A.EF. B.FS. C. End Systolic Diameter. D. End Diastolic Diameter. E. End Systolic Volume. F. Infarct Size. G. Wall Thickness. Sensitivity analysis. A.EF,B.FS,C. End Systolic Diameter, D. End Diastolic Diameter, E. End Systolic Volume, F. Infarct Size and G. Wall Thickness. Supplement Figure 5. Meta-regression analysis of variables that may impact changes in Fractional Shortening. Dichotomous a priori subgroup analysis was performed in a trial investigating the effect of injectable hydrogel combination therapy on infarct size. Mean differences in end systolic diameter in the combination regimen treatment group compared to the injectable hydrogel-only treatment group were grouped by A hydrogel type, B combination therapy, C sex, D small animal model, E time of treatment, F Duration, G MQS. Supplement Figure 6. Meta-regression analysis of variables that may impact changes in LV End Systolic Diameter. Dichotomous a priori subgroup analysis was performed in a trial investigating the effect of injectable hydrogel combination therapy on infarct size. Mean differences in end systolic diameter in the combination regimen treatment group compared to the injectable hydrogel-only treatment group were grouped by A hydrogel type, B combination therapy, C sex, D small animal model, E time of treatment. Supplement Figure 7. Meta-regression analysis of variables that may impact changes in LV End Diastolic Diameter. Dichotomous a priori subgroup analysis was performed in a trial investigating the effect of injectable hydrogel combination therapy on infarct size. Mean differences in end diastolic diameter in the combination regimen treatment group compared to the injectable hydrogel-only treatment group were grouped by A hydrogel type, B combination therapy, C sex, D small animal model, E time of treatment. Supplement Figure 8. Meta-regression analysis of variables that may impact changes in LV End Systolic Volume. Dichotomous a priori subgroup analysis was performed in a trial investigating the effect of injectable hydrogel combination therapy on infarct size. Mean differences in end systolic volume in the combination regimen treatment group compared to the injectable hydrogel-only treatment group were grouped by A hydrogel type, B combination therapy, C sex, D small animal model, E time of treatment, F duration. Supplement Figure 9. Meta-regression analysis of variables that may impact changes in LV End Diastolic Volume. Dichotomous a priori subgroup analysis was performed in a trial investigating the effect of injectable hydrogel combination therapy on infarct size. Mean differences in end diastolic volume in the combination regimen treatment group compared to the injectable hydrogel-only treatment group were grouped by A hydrogel type, B combination therapy, C sex, D time of treatment, E duration. Supplement Figure 10. Meta-regression analysis of variables that may impact changes in Infarct Size. Dichotomous a priori subgroup analysis was performed in a trial investigating the effect of injectable hydrogel combination therapy on infarct size. Mean differences in wall thickness in the combination regimen treatment group compared to the injectable hydrogel-only treatment group were grouped by A hydrogel type, B combination therapy, C sex, D small animal model, E time of treatment, F duration, G MQS, H animal model. Supplement Figure 11.Meta-regression analysis of variables that may impact changes in Wall Thickness. Dichotomous a priori subgroup analysis was performed in a trial investigating the effect of injectable hydrogel combination therapy on wall thickness. Mean differences in wall thickness in the combination regimen treatment group compared to the injectable hydrogel-only treatment group were grouped by A hydrogel type, B combination therapy, C sex, D small animal model, E time of treatment, F duration, G animal model. Supplement Figure 12. Funnel plot for the effect of Injectable hydrogel combination therapy on (A) End Systolic Diameter, (B) End Diastolic Diameter, (C) End Systolic Volume, (D) End Diastolic Volume, (E) Infarct Size, and (F) Wall Thickness. Supplement Figure 13. Funnel plot for the effect of Injectable hydrogel combination therapy on Ejection Fraction in Non-mouse small animal models.